The VanEck Pharmaceutical ETF (NASDAQ:PPH) offers concentrated exposure to established global drugmakers and higher yields, while the State Street SPDR S&P Biotech ETF (NYSEMKT:XBI) provides a diversified, higher-volatility play on smaller-cap biotechnology innovation.
Both funds offer paths into the healthcare sector but serve very different roles in a diversified portfolio. One focuses on the established stability and cash flows of global pharmaceutical giants, while the other captures the high-risk, high-reward nature of early stage biotechnology research. This **** ysis examines which profile fits your strategy.
Metric
XBI
PPH

#pharmaceutical #state